Sa loob ng tatlong magkakasunod na linggo, muling nakapagtala ang Navotas City ng pinakamababang kaso ng COVID-19 kada araw.
Ayon sa OCTA Research Group, mula 12.36 average daily attack rate (ADAR) sa April 25-May 1 at 7.2 sa May 3-9, bumulusok ang ADAR ng lungsod sa 5.99 nitong May 9-14.
“We thank everyone for their contribution to our fight against COVID-19–our frontliners, for their steadfast service in spite of the dangers and challenges their profession entails, and all residents and workers in the city, for their cooperation and support to our policies and programs,” ani Mayor Toby Tiangco said.
“Our declining ADAR shows that the policies we implemented have been effective in protecting our people from COVID-19 and in preventing further transmission of the virus. These include the use of quarantine bands for COVID-positive patients and their close contacts, and the swab test requirement for those who violated the safety health protocols,” dagdag niya.
Gayunman, binalaan ni Tiangco ang mga Navoteño na panatilihin ang kanilang pagbabantay at patuloy na isagawa ang minimum health standards.
“Itis so easy for our COVID numbers to shoot up, especially now that we have fournew and highly transmissible variants. Yet, it takes so much energy, time, andmoney to get those numbers down. This is why we must continue to be extracareful and do our utmost to be protected from the disease,” payo niya.
“Aside from following our safety protocols, have yourself vaccinated if you are 18 years old and above. This week you can choose whether you want AstraZeneca or Pfizer-BioNTech vaccines for your first dose,” sabi pa ng alkalde.
Maaaring magparehistro ang mga residente at mga mangagawa sa lungsod na edad 18 pataas sa libreng COVID vaccines sa http://covax.navotas.gov.ph/. (JUVY LUCERO)
More Stories
SUV SA VIRAL VIDEO GUMAMIT NG PEKENG “7” PROTOCOL PLATE – TULFO
BAGYONG MARCE NAGBABANTA SA LUZON (Matapos ang hagupit nina Julian, Kristine at Leon)
PINOY PADDLERS DAPAT WALANG PUKNAT ANG PROGRAMA SA INTERNATONAL NA EKSENA – ESCOLLANTE